Impact of HIV‐1 viral subtype on disease progression and response to antiretroviral therapy

Abstract

Background Our intention was to compare the rate of immunological progression prior to antiretroviral therapy (ART) and the virological response to ART in patients infected with subtype B and four non‐B HIV‐1 subtypes (A, C, D and the circulating recombinant form, CRF02‐AG) in an ethnically diverse population of HIV‐1‐infected patients in south London. Methods A random sample of 861 HIV‐1‐infected patients attending HIV clinics at King's and St Thomas' hospitals' were subtyped using an in‐house enzyme‐linked immunoassay and env sequencing. Subtypes were compared on the rate of CD4 cell decline using a multi‐level random effects model. Virological response to ART was compared using the time to virological suppression ( 400 copies/ml) following initial suppression. Results Complete subtype and epidemiological data were available for 679 patients, of whom 357 (52.6%) were white and 230 (33.9%) were black African. Subtype B (n = 394) accounted for the majority of infections, followed by subtypes C (n = 125), A (n = 84), D (n = 51) and CRF02‐AG (n = 25). There were no significant differences in rate of CD4 cell decline, initial response to highly active antiretroviral therapy and subsequent rate of virological rebound for subtypes B, A, C and CRF02‐AG. However, a statistically significant four‐fold faster rate of CD4 decline (after adjustment for gender, ethnicity and baseline CD4 count) was observed for subtype D. In addition, subtype D infections showed a higher rate of virological rebound at six months (70%) compared with subtypes B (45%, p = 0.02), A (35%, p = 0.004) and C (34%, p = 0.01) Conclusions This is the first study from an industrialized country to show a faster CD4 cell decline and higher rate of subsequent virological failure with subtype D infection. Further studies are needed to identify the molecular mechanisms responsible for the greater virulence of subtype D.